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Abstract
Background: Generalizable data are needed on the magnitude and determinants of adherence and virological suppression
among patients on antiretroviral therapy (ART) in Africa.
Methods: We conducted a cross-sectional survey with chart abstraction, patient interviews and site assessments in a
nationally representative sample of adults on ART for 6, 12 and 18 months at 20 sites in Rwanda. Adherence was assessed
using 3- and 30-day patient recall. A systematically selected sub-sample had viral load (VL) measurements. Multivariable
logistic regression examined predictors of non-perfect (,100%) 30-day adherence and detectable VL (.40 copies/ml).
Results: Overall, 1,417 adults were interviewed and 837 had VL measures. Ninety-four percent and 78% reported perfect
adherence for the last 3 and 30 days, respectively. Eighty-three percent had undetectable VL. In adjusted models,
characteristics independently associated with higher odds of non-perfect 30-day adherence were: being on ART for 18
months (vs. 6 months); younger age; reporting severe (vs. no or few) side effects in the prior 30 days; having no
documentation of CD4 cell count at ART initiation (vs. having a CD4 cell count of ,200 cells/mL); alcohol use; and attending
sites which initiated ART services in 2003–2004 and 2005 (vs. 2006–2007); sites with $600 (vs. ,600 patients) on ART; or
sites with peer educators. Participation in an association for people living with HIV/AIDS; and receiving care at sites which
regularly conduct home-visits were independently associated with lower odds of non-adherence. Higher odds of having a
detectable VL were observed among patients at sites with peer educators. Being female; participating in an association for
PLWHA; and using a reminder tool were independently associated with lower odds of having detectable VL.
Conclusions: High levels of adherence and viral suppression were observed in the Rwandan national ART program, and
associated with potentially modifiable factors.
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Introduction
In recent years, HIV care and treatment programs in sub-
Saharan Africa have shifted from an emergency response with a
focus on quickly initiating the sickest HIV-infected patients on
antiretroviral therapy (ART) to building sustainable programs
which provide lifelong treatment to very large numbers of patients
across the HIV disease spectrum. Among the pillars of sustainable
HIV treatment programs is the ability of patients to achieve and
maintain adequate adherence to ART for life. Adherence is critical
for improving the patient’s own prognosis [1,2], minimizing
development of drug resistant HIV [3,4], and reducing the risk of
HIV transmission to HIV-negative sexual partners [5,6].
In contrast to the growing literature on levels and determinants
of patient retention from nationally representative or large multi-
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site samples of ART patients in Africa [7–10], generalizable data
on patient adherence to ART in sub-Saharan Africa are limited. A
meta-analysis of 27 small observational studies (median sample
size = 100 patients) conducted in Africa during a very early phase
of ART scale-up reported adequate adherence among 77% of
patients [11]. More recent single-site and small multi-site reports
from service-delivery settings in the region have reported optimal
adherence among 25% to 94% of patients [2,12–14]. Additionally,
virologic monitoring, an objective measure of adherence used
regularly for patient management and program evaluation in high-
income settings, is rarely conducted in Africa. A recent systematic
review of 89 African studies with any virologic data conducted
largely in urban settings reported undetectable viral loads among
78% of patients after six months of ART, 76% after 12 months,
and 67% after 24 months [15].
Rwanda has an estimated adult national HIV prevalence of 3%
(2% in men and 4% in women) [16] and is one of three low- and
middle-income countries with a generalized HIV epidemic to have
achieved universal access to ART [17]. By December 2010,
91,984 people were receiving ART, representing 88% of the
population estimated to be in need of treatment [17]. As in many
sub-Saharan African countries, the Rwandan national ART
program expanded rapidly from 4 clinics in 2002 to 328 clinics
by 2010 [18,19]. An evaluation of the national program for the
2004–2005 period revealed that 92% and 84% of patients were
retained six and 12 months after ART initiation, respectively [9].
Data on adherence are available from two single-site studies, both
conducted in the capital city of Kigali, and suggest very high levels
of perfect adherence at 12 months [20,21]. Neither study assessed
determinants of optimal adherence or included other measures of
adherence. We use data from a large, nationally representative,
multi-site study of the magnitude and determinants of self-reported
adherence, treatment interruptions, and virological suppression
among patients remaining on ART for 6, 12 and 18 months in the
Rwandan national ART program.
Methods
Study Design, Population and Sampling
By the end of February 2007, approximately 18 months prior to
study start, 113 health facilities, including 79 public facilities and
34 faith-based facilities, were providing ART, and according to the
national monitoring and evaluation system, 9,693 adults were on
ART: 3,628 for 6 months 3,086 for 12 months, and 2,979 for 18
months. From September 2008 to April 2009, we conducted a
cross-sectional study in 20 of the 113 facilities.
Sample size calculations were based on the expected proportion
of patients reporting perfect adherence 18 months after ART
initiation as that proportion was expected to be lower than those at
6 and 12 months after ART initiation. Assuming an 18-month
perfect adherence rate of 85%, a precision of 65% or less, a
design effect of 1.5, and a refusal rate of 25%, as well as
application of a finite population correction factor and logistical
considerations, a sample of 1,798 patients spread across 20 sites
was considered adequate.
Study participation was restricted to adults aged $18 years at
study enrolment who had initiated first-line ART at one of the
study sites 6, 12 and 18 months [+/22 months] prior to data
collection and were still receiving treatment at their initiating site,
or transferred into one of the study sites within 30 days of ART
initiation and were still receiving it at that site. Patients who died,
were lost to follow-up (defined according to national guidelines as
no clinic visit for 90 days or more since the last documented
visit), transferred to another clinic before study start, as were those
who continued in care at their initiating site but had stopped ART
prior to data collection. Patients who transferred into one of the
study sites more than 30 days after initiating ART were also
excluded to minimize potential misclassification bias when
identifying site-level determinants of patient outcomes.
Stratified multi-stage cluster sampling was used, with sites as
clusters, and six strata according to type of facility (public and
faith-based) and time on ART (6, 12 and 18 months). The first
stage of sampling involved randomly selecting 14 public and 6
faith-based sites from the 113 sites providing ART services 18
months prior to study start, with the total number of each type of
site determined based on the relative contribution of each of those
types of sites to the total number of adults on ART in Rwanda
recorded in the national monitoring and evaluation system. In the
second stage of sampling, patient registers and charts at the
selected sites were used to create sampling frames of all eligible
patients per strata. The desired sample size per strata was
determined based on the relative contribution of eligible patients
in each stratum to the total number of eligible patients identified.
The sample per strata was divided across sites based on the relative
contribution of eligible patients at each site to the total number of
patients required per strata. Potential participants were selected
from the site-specific sampling frames using simple random
sampling. Individual records were reviewed for each potential
participant selected using random sampling to confirm that they
met the study eligibility criteria. If a patient was found to be
ineligible, she or he was replaced by another eligible patient from
the appropriate site-specific sampling frame using a random
replacement scheme.
Site staff otherwise unaffiliated with the study contacted the
selected patients confirmed to meet the study eligibility criteria at
home and invited them to return to the health facility to learn
more about the study. For patients who presented to the clinic,
study staff provided more details about the study, obtained written
informed consent, and completed interviews. Every alternate
participant was included in the viral load sub-sample, with blood
draw occurring immediately after the interview. Participants
received the equivalent of US $4.50 to cover transport to the
clinic to participate in the study. Patients who did not present to
the facility following the invitation by the site staff, refused to
participate after presenting to the facility, or could not be located
were not replaced.
Study Procedures
Participant interview. Trained interviewers conducted face-
to-face interviews which lasted approximately 45 minutes using a
closed-ended questionnaire translated into Kinyarwanda. The
questionnaire covered socio-demographic characteristics, psycho-
social support, ART-related side effects, health behaviors and
beliefs. Adherence was measured by patient recall of the number
or percentage of doses taken during the three and 30 days prior to
interview. Specifically, three-day patient recall was assessed using
questions developed by the Adult AIDS Clinical Trials Group
which have been previously validated in the United States [22]
and used successfully in low-income settings [14,23–25]. For each
medication prescribed, patients were asked to indicate whether
they took the required doses during each of the three days
preceding the interview. These questions were preceded by a
statement that many people do not take their medication perfectly
all of the time in an effort to elicit accurate reporting. Thirty-day
recall was assessed using an ordinal visual analogue scale modeled
on a continuous numeric scale validated in the United States [26]
and a categorical pictorial scale developed by ICAP staff in
Mozambique [27]. Patients were presented with a line anchored
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with cups at 0 (empty cup) and 10 (full cup), provided with
examples of what 0, 50 and 100% adherence would represent, and
asked to show the percentage of doses of all ART medications they
took relative to that prescribed for the 30-day period prior to the
interview. In order to assess treatment interruptions, patients were
also asked the number of times they had missed taking all of their
medication for three or more days since starting ART.
Abstraction of clinical data. Interviewers used a structured
tool to abstract data on ART regimens, clinic visits and CD4,
weight and WHO stage assessments since enrollment into care
from patient medical charts and pharmacy records.
Viral load assessment. For patients selected into the viral
load sub-sample, blood specimens were collected by the site
phlebotomist in PPT or EDTA tubes (Becton Dickinson, San Jose,
CA, USA). Depending on the distance of the site from the
National Reference Lab (NRL) in Kigali, samples were either
transported directly to the NRL for centrifuging within four hours
of being drawn, or centrifuged at the site or a nearby District
Hospital within four hours and then transported to the NRL
within 18 hours. Plasma levels of HIV RNA were quantified by
real-time PCR using a Cobas TaqMan 48 machine (Roche
Diagnostic Systems, NJ, USA) with a detection limit of 40 RNA
copies/mL.
Site assessment. Data on facility- and program-level factors
that may impact adherence at the patient level were obtained for
each site. Interviewers completed a structured assessment tool via
discussion with the director of the facility or the HIV clinic, or
another staff member familiar with the day-to-day operations of
the HIV clinic.
Data Management and Analysis
Data were double data entered into a Questionnaire Design
Software (QDSTM) (NOVA Research Company, Bethesda, MD)
database and analyzed using survey procedures in SAS Version
9.2 (SAS, Cary, NC) designed for complex survey data. Sampling
weights accounting for the probability that a site would be selected
from the 113 in the sampling frame (by type of site: public and
faith-based) and the probability that a patient would be selected
from the site-specific sampling frame of all patients on ART (by
time on ART: 6, 12, and 18 months) were used together with finite
population correction factors in all analyses to obtain nationally
representative estimates. Descriptive statistics were used to
describe study sites and patient characteristics by time since
ART initiation. Principal components analysis considering infor-
mation on dwelling conditions and household assets was used to
create a poverty index which was then divided into tertiles,
representing the poorest, middle and least poor respondents. An
index of side effects was generated by summing scaled responses to
whether each of 19 side effects were experienced and if so, their
severity, in the 30 days prior to interview; the index was
categorized based on the 25th and 75th percentile cut-offs,
representing whether the respondent experienced no or few side
effects, moderate side effects or severe side effects. If CD4 counts
were not available from the visit at which ART was initiated,
results from up to three months before or after the date of ART
initiation were used.
Primary outcome measures were three-day adherence, 30-day
adherence, treatment interruptions, and viral load at the time of
interview. Adherence and viral load were treated both continu-
ously and categorically using clinically relevant thresholds.
Treatment interruptions were examined using rates per person-
year on ART. The four measures were compared across time since
ART initiation strata using descriptive statistics, as appropriate.
Logistic regression analysis was used to identify patient- and site-
level characteristics associated with two of those outcomes: sub-
optimal 30-day adherence and detectable viral load. Sub-optimal
adherence was defined as patient report of having taken less than
100% of prescribed doses in the 30 days prior to interview, and
viral loads of more than 40 copies/mL were designated as
detectable. Non-collinear factors significant at the a#0.2 level in
unadjusted models were introduced in multivariable models.
Variables that were statistically significant at a#0.05 and that
contributed to the overall goodness of fit of the model were
retained in the final models. If not independently associated with
the outcome, time since ART initiation, age, sex and CD4 at ART
initiation were forced into the final models regardless of their
statistical significance. Characteristics associated with three-day
adherence and treatment interruptions were not assessed due to
insufficient variability in the data.
Ethical Considerations
The study protocol was approved by the National AIDS
Commission, the National Ethics Committee and the National
Institute of Statistics in Rwanda, as well as by the Institutional
Review Board at Columbia University. All participants provided
written informed consent prior to interview, and when applicable,
prior to blood draw for viral load assessment.
Results
According to government data, a total of 1,951 patients were
believed to have started ART 6, 12 and 18 months prior to data
collection at the 20 study sites, 1,798 (92%) of whom were
randomly selected for inclusion in the study. Of those selected for
inclusion, 1,472 (82%) were confirmed to meet the study eligibility
criteria following individual record review, and 1,417 (96%) of
those patients could be located and agreed to participate, including
571 (40%), 491 (35%) and 355 (25%) who started ART 6, 12 and
18 months prior to data collection, respectively. A total of 837
(59%) of the 1,417 participants received viral load assessments,
including 331 (40%) who had been on ART for 6 months, 284
(34%) on for 12 months and 222 (27%) on for 18 months (Figure 1).
After applying the sampling weights, the total population was
6,996, with 2,724 (39%), 2,353 (34%) and 1,921 (27%) in the 6,
12, and 18 months on ART groups, respectively. The weighted
viral load population was 4,184 (60%), with 1,598 (38%) 1,336
(32%) 1,250 (30%) in the 6, 12, and 18 months on ART groups,
respectively.
Site Characteristics
Of the 20 study sites, 14 (70%) were public sector and six (30%)
were faith-based, as per the study design. Eleven (55%) were
located in rural areas. There were 14 (70%) primary-level health
centers and six (30%) secondary-level hospitals. Seven (35%) sites
had started providing ART services in 2003 or 2004, seven (35%)
in 2005 and six (30%) in 2006 or 2007. Six (30%) sites had active
peer educator programs and ten (53%) conducted routine home
visits for patients.
Population Characteristics
Table 1 shows the characteristics of the population on ART for
6, 12 and 18 months in Rwanda at the time of data collection.
There were few statistically significant differences in the distribu-
tion of population characteristics by time since ART initiation.
The majority of the population was female (65%) and, on average
was 38 years old and had completed 5 years of school. Many
patients did not have information in their medical records on their
WHO stage (37%) or CD4 cell count (16%) at ART initiation,
ART Adherence at 6, 12 and 18 Months in Rwanda
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Figure 1. Participant selection and recruitment.
doi:10.1371/journal.pone.0053586.g001
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Table 1. Patient characteristics by time on ART.
Total 6 months 12 months 18 months




% N Weighted % p-value
1417 100.0 571 40.0 491 35.0 355 25.0
Sociodemographic Factors
Sex
Male 499 35.0 201 35.1 170 35.2 128 34.5 0.982
Female 913 65.0 369 64.9 319 64.8 225 65.5
Missing 5 1 2 2
Age
Mean years, SE 38.1 0.3 38.2 0.4 38.4 0.4 37.4 0.6 0.522
Age groups
18–24 years 101 6.3 41 6.0 35 6.4 25 6.6 0.960
25–34 years 480 32.7 191 32.7 161 30.4 128 35.6 0.500
35–44 years 531 36.9 208 35.0 182 37.5 141 38.7 0.749
$45 years 305 24.1 131 26.3 113 25.7 61 19.1 0.146
Missing 0 0 0 0
Education
Mean years, SE 5.0 0.2 4.9 0.4 4.7 0.3 5.5 0.3 0.291
Education levels
None 321 26.4 129 25.3 114 29.5 78 24.1 0.577
Some 1096 73.6 442 74.7 377 70.5 277 75.9
Missing 0 0 0 0
Marital status
Married/living with partner 771 53.5 307 52.5 275 54.7 189 53.7 0.824
Separated/divorced/Widowed/not
living with partner
515 38.2 206 39.2 178 37.9 131 37.3
Never married 125 8.3 57 8.3 37 7.4 31 9.2
Missing 6 1 1 4
Number of household members
Mean number, SE 5 0.0 5 0.1 5 0.1 5 0.1 0.841
Missing 7 3 1 3
Household poverty index
Poorest 490 42.6 198 41.0 180 47.1 112 39.3 0.880
Less poor 455 33.4 184 35.6 152 30.2 119 34.1
Least poor 472 24.0 189 23.4 159 22.7 124 26.6
Missing 0 0 0 0
Treatment-related Factors
WHO stage at ART initiation
I & II 523 38.1 184 32.8 182 41.6 157 41.2 0.001
III & IV 373 24.9 100 16.9 150 25.8 123 35.0
Missing 521 37.0 287 50.3 159 32.6 75 23.8
CD4 count (cells/mL) at ART
initiation
Median, IQR 221.9 149.9–293.7 258.0 184.1–309.8 209.2 139.6–287.8 191.8 130.8–270.3 ,0.001
,200 560 35.0 156 25.0 224 40.0 180 43.2 0.004
$200 651 49.1 318 57.8 205 46.4 128 39.9
Missing 206 15.9 97 17.1 62 13.6 47 16.9
Current ART regimen
Nevirapine-based 1220 89.1 507 91.7 411 85.7 302 89.4 0.127
Efavirenz-based 167 10.3 53 7.5 66 13.6 48 10.1
Other 9 0.7 3 0.7 3 0.7 3 0.4
ART Adherence at 6, 12 and 18 Months in Rwanda
PLOS ONE | www.plosone.org 5 January 2013 | Volume 8 | Issue 1 | e53586
with more missing information on WHO stage observed among
those who started ART more recently than those who had been on
ART for a longer period of time (50%, 33%, and 24% missing for
6, 12, 18 month cohorts, respectively). Among those with
information available on their disease stage at ART initiation,
there was variation by time since ART initiation, with patients on
ART for a longer period of time starting ART in a more
compromised health stage (median CD4 counts of 258, 209, and
192 cells/ml for 6, 12, 18 month cohorts, respectively). The
majority (89%) of patients were on Nevirapine-based regimens and
on average took 1.6 pills per day. About one-quarter (26%)
reported severe side effects in the 30 days before interview. Nearly
(94%) all believed ART was ‘‘very effective’’, more than half (57%)
used at least one ART reminder tool, with alarm clocks used most
often by 22% of the population, and 53% participated regularly in
PLWHA support groups. Thirteen percent reported consuming
alcohol on at least one day in the week prior to data collection.
Levels of Self-reported Adherence, Treatment
Interruptions and Viral Suppression
As shown in Table 2, 94% of the population reported perfect
three-day adherence. Perfect adherence in the 30 days preceding
the interview was reported by 78% of the population. An
additional 11% took 90–99% of all their pills in the 30 days prior
to data collection, 7% took 80%–89, and 4% took less than 80%.
The rate of treatment interruptions was one 1.1 per person-year
on ART. Eighty-three percent of the population had an
undetectable viral load, 9% had a viral load of 41–500 copies/
mL and 8% had a viral load of .500 copies/mL. While none of
these measures varied by time on ART, significant differences
Table 1. Cont.
Total 6 months 12 months 18 months




% N Weighted % p-value
Missing 21 8 11 2
Number of daily pills
Median, IQR 1.6 1.3–1.9 1.6 1.3–1.8 2.0 2.0–2.0 1.6 1.3–1.8 0.043
Missing 98 34 32 32
Side effects index
No or few side effects 371 26.1 154 27.1 114 24.0 103 27.4 0.789
Moderate side effects 690 48.1 276 45.7 247 51.4 167 47.6
Severe side effects 350 25.7 139 27.2 127 24.6 84 25.0
Missing 6 2 3 1
Psychosocial and Behavioral Factors
Perception of ART effectiveness
in keeping respondent healthy
Very effective 1334 94.0 530 91.4 469 96.6 335 94.6 0.002
Somewhat effective/not effective at
all
83 6.0 41 8.6 22 3.4 17 5.4
Missing 0 0 0 0
Participates regularly in PLWHA
meeting
749 52.5 246 46.7 234 52.7 181 60.6 0.181
Missing 0 0 0 0
Frequency of alcohol
consumption
A lot (4–7 days) 7 1.3 4 1.0 1 0.2 2 3.2 0.115
Some (1–3 days) 49 11.7 17 7.9 22 16.3 10 12.0
Never 290 87.0 118 91.1 106 83.5 66 84.8
Missing 6 3 2 1
Reminder tools to take ART
No tools 522 42.6 202 44.2 186 42.4 134 40.5 0.846
Cell phone 243 13.1 99 13.4 78 12.8 66 13.0 0.991
Alarm clock 322 21.9 141 22.6 107 21.6 74 21.4 0.962
Paper diary 32 2.0 12 1.7 9 1.6 11 2.9 0.606
Radio 271 17.8 115 18.2 92 16.1 64 19.2 0.761
Other 85 5.4 33 4.4 31 6.2 21 5.9 0.675
Use any tool 894 57.4 369 55.8 304 57.6 221 59.5 0.846
Missing 1 1 1 1
doi:10.1371/journal.pone.0053586.t001
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were observed by site (Figure 2), with perfect 3-day adherence
ranging from 84% to 100% (p = 0.0013) across sites, perfect 30-
day adherence ranging from 50% to 98% (p = 0.0598), treatment
interruptions ranging from 0.1 to 3.1 per person-year on ART
(p,0.0001), and viral suppression ranging from 70% to 100%
(p = 0.0552).
Characteristics Associated with Non-perfect Adherence
and Detectable Viral Load
Table 3 shows characteristics associated with reporting non-
perfect 30-day adherence and having a detectable viral load in
unadjusted and adjusted analyses. In adjusted models controlling
for sex, characteristics independently associated with higher odds
of non-perfect 30-day adherence were being on ART for 18
months vs. 6 months (AOR = 1.75, 95% CI [1.18–2.60]), being
aged 18–24, 25–34 and 35–44 vs. $44 (AOR = 2.00, 95% CI
[1.05–3.83]; AOR = 2.51, 95% CI [1.50–4.20]; AOR = 2.06, 95%
CI [1.28–3.30], respectively), reporting severe vs. no or few side
effects in the prior 30 days (AOR = 2.18, 95% CI [1.47–3.24]);
having no documentation of CD4 cell count at ART initiation vs.
having a CD4 cell count of ,200 cells/mL (AOR = 1.65, 95% CI
[1.03–2.64]); alcohol use (AOR = 1.55, 95% CI [1.01–2.38]); and
attending sites which initiated ART services in 2003–2004 and
2005 vs. 2006–2007 (AOR = 1.82, 95% CI [1.07–3.09];
AOR = 2.11, 95% CI [1.23–3.62], respectively); sites with $600
vs. ,600 patients currently on ART (AOR = 1.63, 95% CI [1.20–
2.23]) or those with peer educators (AOR = 2.94, 95% CI [1.87–
4.64]). Participation in an association for people living with HIV/
Figure 2. Proportion (and 95% CI) of patients reporting 100% adherence during 3 days or 30 days preceding interview, rate of
treatment interruptions (missing ART for $3 days) per person-year on ART (95% CI), and proportion (95% CI) of patients with
undetectable viral load by site.
doi:10.1371/journal.pone.0053586.g002
Table 2. Adherence by time on ART.
Total 6 months 12 months 18 months
N Weighted % N Weighted % N Weighted % N Weighted % p-value
1417 100.0 571 40.0 491 35.0 355 25.0
Patient 3-day recall
100% adherent (95% CI) 1416 93.8 (92.8–94.8) 553 94.1 (92.8–95.4) 456 95.0 (93.9–96.5) 331 91.7 (88.9–94.4) 0.238
90–99% adherent 57 3.1 22 2.3 22 3.2 13 4.2 0.533
80–89% adherent 21 1.3 6 0.6 9 1.3 6 2.1 0.139
,80% adherent 19 1.9 10 3.0 4 0.5 5 2.0 0.083
Median, IQR 94.7 92.0–97.3 94.7 92.0–97.3 94.7 92.1–97.4 94.5 91.8–97.3 0.265
Missing 1 0 1 0
Patient 30-day recall
100% adherent (95% CI) 1086 77.6 (74.9–80.2) 422 78.5 (74.1–82.9) 376 79.4 (75.2–83.6) 268 74.0 (68.6–79.4) 0.808
90–99% adherent 163 11.3 64 10.8 54 9.2 45 14.6 0.265
80–89% adherent 103 6.7 39 6.1 34 7.6 30 6.4 0.854
,80% adherent 56 4.1 25 4.5 22 3.3 9 4.4 0.859
Median, IQR 93.6 90.3–96.8 93.6 90.4–96.8 93.7 90.6–96.9 93.2 89.3–96.6 0.938
Missing 9 1 5 3
Viral load (copies/mL)
Number with viral load 837 59.8 331 58.7 284 56.8 222 65.1
Undetectable/#40 (95% CI) 693 83.3 (81.7–90.7) 275 82.4 (79.7–85.0) 232 81.8 (78.5–85.1) 186 86.2 (81.7–90.7) 0.548
41–500 81 8.9 35 10.8 28 9.4 18 6.1 0.558
.500 63 7.7 21 6.9 24 8.8 18 7.7 0.558
Median VL among detectable VL, IQR 316.7 86.7–5426.8 248.2 77.0–1318.4 274.1 84.6–6136.6 1498.8 113.1–55656.0 0.300
Rate of treatment interruptions (missing ART for $3 days) per person-year on ART
Rate, SE 1.1 0.1 1.2 0.2 1.1 0.2 0.8 0.2 0.147
Missing 6 2 1 3
doi:10.1371/journal.pone.0053586.t002
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Table 3. Bivariate and multivariate association of patient-and site level predictors and self-reported 30-day non-adherence
(,100% adherent) and detectable viral load (.40 copies/mL).
Non-adherence Detectable viral load
Unadjusted Adjusted Unadjusted Adjusted
N = 1408 N = 1395 N = 835 N = 828
20 sites 20 sites 20 sites 20 sites
OR 95% CI AOR 95% CI OR 95% CI AOR 95% CI
PATIENT LEVEL
FACTORS
Duration on ART (ref = 6 months)
12 months 0.95 0.57–1.57 1.31 0.89–1.94 1.04 0.79–1.38 1.07 0.73–1.55
18 months 1.28 0.75–2.20 1.75 1.18–2.60 0.75 0.50–1.14 0.79 0.47–1.33
Sociodemographic Factors
Age (ref = $45 yrs)
18–24 yrs 1.87 1.31–2.67 2.00 1.05–3.83 2.12 1.08–4.14 2.56 0.98–6.74
25–34 yrs 2.79 2.16–3.60 2.51 1.50–4.20 1.41 0.83–2.40 1.74 0.75–4.06
35–44 yrs 1.94 1.53–2.46 2.06 1.28–3.30 0.96 0.60–1.55 1.11 0.52–2.39
Sex (ref = Male)
Female 1.04 0.82–1.33 0.90 0.57–1.43 0.68 0.48–0.97 0.52 0.29–0.94
Education (ref = no education)
Some education 1.52 1.00–2.32 1.56 1.07–2.28
Current marital status (ref = Married/
living together)
Other 0.75 0.57–0.99




Poverty index (ref = most poor)
Middle 1.42 1.07–1,89
Least poor 1.63 1.30–2.05
Treatment-related Factors
Side effects in past 30 days (ref = none/
few)
Moderate 1.36 1.01–1.84 1.45 0.91–2.31
Severe 2.01 1.56–2.59 2.18 1.47–3.24
CD4 count at ART initiation (ref = ,200)
$200 1.05 0.76–1.44 1.31 0.86–1.98 0.87 0.65–1.81 0.85 0.50–1.44
Missing 1.22 0.89–1.67 1.65 1.03–2.64 1.15 0.77–1.70 1.13 0.58–2.20
Psychosocial and Behavioral Factors
Perception of ART effectiveness
(ref = effective)
Not effective 2.14 1.42–3.2
Participates in PLWHA association
(ref = no)
Yes 0.61 0.52–0.73 0.66 0.48–0.90 0.39 0.28–0.56 0.39 0.24–0.65
Frequency of alcohol consumption
(ref = none)
Some or a lot 1.65 1.27–2.16 1.55 1.01–2.38
Uses any reminder tool to take ART
(ref = no)
Yes 0.59 0.45–0.78 0.45 0.29–0.70
SITE LEVEL
FACTORS
Facility ownership (ref = Faith-based)
Public 0.72 0.57–0.93
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AIDS (AOR = 0.60, 95% CI [0.42–0.87]); and receiving care at
sites which regularly conduct home-visits (AOR = 0.60, 95% CI
[0.42–0.87]) were independently associated a lower risk of non-
adherence.
In adjusted models controlling for duration on ART, age and
CD4 count at ART initiation, higher odds of having a detectable
VL were observed among patients at sites with peer educators
(AOR = 2.01, 95% CI [1.40–2.88[). Being female (AOR = 0.52,
95% CI [0.29–0.94]); participating in an association for people
living with HIV/AIDS (AOR = 0.39, 95% CI [0.24–0.65]); and
using a reminder tool (AOR = 0.45, 95% CI [0.29–0.70]) were
negatively associated with having a viral load of more than 40
copies/mL.
Discussion
As the first nationally representative study on adherence,
treatment interruptions and viral suppression among patients on
ART in sub-Saharan Africa, this study provides important insights
on program outcomes previously not sufficiently described in the
context of rapid scale-up of HIV services. Additionally, as Rwanda
is one of the small handful of countries in sub-Saharan Africa that
has achieved universal treatment coverage, we were able to assess
whether program quality can be maintained as countries reach
that goal. Reassuringly, very high program quality was observed.
Overall, across the population on ART for 6, 12 and 18 months in
Rwanda, 94% reported perfect three-day adherence and 78%
reported perfect 30-day adherence. This finding is consistent with
that reported in smaller studies in East Africa [1,14], but lower
than that reported from single-site studies in Kigali [11,20,21].
Additionally, reports of treatment interruptions of three days or
more were rare, resulting in a low rate of interruptions of one per
person-year on ART. Patients in our study also demonstrated a
high degree of viral suppression with 83% having undetectable
viral loads, considerably higher than that observed in a large
sample from a South African program setting where 62% of adult
patients had viral load #400 copies/mL at 12 months [2].
A number of patient characteristics were associated with higher
odds of non-adherence, including longer time on ART, younger
age, experiencing severe side effects, not having a CD4 count at
ART initiation, and alcohol use. Patients who had been on ART
for 18 months had 75% higher odds of non-adherence compared
to those who had been on ART for 6 months. This trend was also
observed among adults in a South Africa [2] and suggests that
patients who have been on ART longer should be targeted for
adherence support interventions. The association between youn-
ger age and increased risk for non-adherence has also been
demonstrated by other studies [2,25] implying a need for focused
interventions to support adherence among younger adults. Side
effects are a recognised barrier to ART adherence [28] and should
be effectively managed for better adherence. Encouragingly, a
large proportion of patients (84%) in a task shifting study in
Rwanda had side effects regularly assessed [29], and this practice
should be encouraged at all clinics. The association between lack
of a CD4 at ART initiation and higher odds of non-adherence
may mean that patients fail to grasp the severity of their illness and
the necessity of treatment. Understanding one’s HIV disease and
medications for managing may support patient adherence [30–
32]. The detrimental impact of alcohol consumption on ART
adherence has been well documented in other studies [28,33–36].
Assessment for significant alcohol use should be integrated into
routine adherence counselling and prevention with positives
interventions [37].
Several patient characteristics were also independently associ-
ated with lower odds of non-adherence and having a detectable
viral load, and suggest avenues for intervention among patients
experiencing adherence problems. Indeed, participation in a
PLWHA association, which we found to be associated with
Table 3. Cont.
Non-adherence Detectable viral load
Unadjusted Adjusted Unadjusted Adjusted
N = 1408 N = 1395 N = 835 N = 828
20 sites 20 sites 20 sites 20 sites
OR 95% CI AOR 95% CI OR 95% CI AOR 95% CI
Site location (ref = rural)
Urban 2.10 1.61–2.73 1.46 1.12–1.90
Site type (ref = health centre)
Hospital 1.41 1.06–1.88
Year ART services initiated (ref = 2006–
2007)
2003–2004 1.39 1.05–1.83 1.82 1.07–3.09
2005 1.68 1.17–2.41 2.11 1.23–3.62
Site ART enrollment (ref = ,600)
$600 patients 1.40 1.11–1.77 1.63 1.20–2.23
Peer educator program (ref = no)
Yes 1.79 1.33–2.40 2.94 1.87–4.64 1.77 1.36–2.30 2.01 1.40–2.88
Home support visits for PLWHA (ref = no)
Yes 0.60 0.46–0.79 0.60 0.42–0.87
*Note: The variables cohort, CD4 at initiation, sex and age have been forced to remain in the model.
doi:10.1371/journal.pone.0053586.t003
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decreased risk of non-adherence and having a detectable viral
load, may encourage positive behaviour among patients on ART.
Additionally, while use of reminder tools was not associated with
self-reported adherence, their use was significantly associated with
low odds of having a detectable viral load, providing further
evidence that they promote adherence [38–40]. Women were also
less likely to have a detectable viral load, consistent with a recent
study from Uganda, but no gender differential was observed in
reporting of non-adherence. This is consistent with data from a
smaller study in Uganda [41] and suggests either a true sex
difference in response to ART or misreporting of adherence
among men.
Significant variability by site was observed in all study outcomes,
suggesting opportunities exist for site-level interventions to
optimize outcomes. Patients attending high volume sites had
higher odds of non-adherence probably due to insufficient staff
time to focus on this aspect of patient management. Patients
attending sites that had started implementation of ART services
earlier in scale-up also had higher odds of non-adherence than
those attending less mature sites. More research is needed to
understand this finding, including assessing the contribution of
health worker fatigue. Such sites might benefit from implementing
supportive home visits, which were associated with reduced odds
of non-adherence in our study. In contrast, we found that patients
attending sites with peer educator programs had higher odds of
non-adherence and of having a detectable viral load. While some
studies suggest that peer support is associated with better
adherence, particularly if it includes implementation of directly
observed therapy [42,43], a recent large cluster randomised study
from Uganda found no impact of peer educators on adherence
and viral suppression up to 96 weeks [44]. As the cross-sectional
nature of our study precludes us from ruling out reverse causality,
such that sites which experienced poor adherence and treatment
response preferentially implemented peer educator programs,
further studies are needed to understand the role of peer educator
programs in this setting.
Our study has several important strengths. To our knowledge, it
is the first nationally representative assessment of adherence, viral
suppression, and treatment interruptions among patients on ART
in Africa and possibly worldwide. Having both patient-level and
site-level data allowed us to explore a wide range of correlates of
optimal adherence and viral suppression. A few limitations should
be noted, however. While the objective of our study was to assess
outcomes among patients who remained on treatment for 6, 12
and 18 months, it is likely that those who were not retained had
worse adherence and more treatment interruptions, and thus were
less likely to achieve viral suppression. Similarly, while non-
participation was extremely rare and restricted to 55 (3.7%) of
patients confirmed to be eligible for the study, these patients likely
had worse outcomes than study participants; indeed, assuming all
such patients had non-perfect adherence and detectable viral
loads, the overall weighted proportion of participants with perfect
3-day and 30-day adherence, and undetectable viral load would be
90%, 74%, and 78%, respectively. Additionally, lack of variation
in some site-level variables precluded their inclusion in multivar-
iable models. Finally, due to financial constraints, we were unable
to perform viral load assessments for all patients which limited our
power to detect significant associations when modelling predictors
of detectable viral load.
In conclusion, high levels of self-reported adherence and
virological suppression, and low rates of treatment interruption
were observed among a nationally representative sample of
patients on ART for 6, 12 and 18 months in the Rwandan
national program. Our results suggest that strategies to maximize
adherence in these settings should include reminder tools, alcohol
screening and treatment, participation in PLWHA associations
and supportive home visits.
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